Sanfilippo Syndrome Patients, Drug Developers At Odds With US FDA Guidance

 
• By Sue Sutter
  
Barrier
An FDA draft guidance has become a barrier to developing drugs for MPS III, advocates and sponsors say. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approval Standards

More from Pathways & Standards